Serenity Bioworks
San Francisco
About Serenity Bioworks
Serenity is developing antibody mimetics for targeted protein degradation. The company's innovative approaches combine advanced display techniques with in silico predictions, harnessing the power of computational methods to streamline and optimize the discovery process.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $2.0M
- Funding stage: Seed
- Last round: Seed (May 2019)
- Website: serenitybioworks.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/serenity-bioworks-99391 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.